Evidence map›Paper›PMID 33723507›Full record

ArticleToxicology reports2021

Use of ivermectin in the treatment of Covid-19: A pilot trial.

Henrique Pott-Junior, Mônica Maria Bastos Paoliello, Alice de Queiroz Constantino Miguel, Anderson Ferreira da Cunha, Caio Cesar de Melo Freire, Fábio Fernandes Neves, Lucimar Retto da Silva de Avó, Meliza Goi Roscani, Sigrid De Sousa Dos Santos, Silvana Gama Florêncio Chachá

Retracted Registry-linked trialOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. It is linked to trial NCT04431466 (Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection), which is not on this map. Cited by 22 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 7 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04431466 phase2terminatednot on this map

Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2)

TypeinterventionalSponsorUniversidade Federal de Sao CarlosRan2020 to 2020Enrolled32ConditionsCoronavirus InfectionArmsIvermectin, Standard of Care
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 7 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Ivermectin for preventing and treating COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Multipurpose Drugs Active Against BothFrontiers in cellular and infection microbiology · 2021
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Henrique Pott-JuniorDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Mônica Maria Bastos PaolielloDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, 10461, Bronx, New York, United States.
Alice de Queiroz Constantino MiguelUniversity Hospital of the Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Anderson Ferreira da CunhaDepartment of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.
Caio Cesar de Melo FreireDepartment of Genetics and Evolution, Federal University of São Carlos (UFSCar); 13565-905, São Carlos, São Paulo, Brazil.
Fábio Fernandes NevesDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Lucimar Retto da Silva de AvóDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Meliza Goi RoscaniDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Sigrid De Sousa Dos SantosDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Silvana Gama Florêncio ChacháDepartment of Medicine, Federal University of São Carlos (UFSCar), 13565-905, São Carlos, São Paulo, Brazil.
Universidade Federal de São Carlos · BRAlbert Einstein College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19.

methodsPatients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466).

resultsA total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests.

conclusionsIvermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.

Indexed as

COVID-19IvermectinSARS-CoV-2

Identifiers

PMID33723507
PMCPMC7942165
OpenAlexW3134585354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.